Epigenetic therapy leaps ahead with specific targeting of EZH2. - Wikidata - awgldk - TriplyDB

Epigenetic therapy leaps ahead with specific targeting of EZH2.

Epigenetic therapy leaps ahead with specific targeting of EZH2.

http://www.wikidata.org/entity/Q34034378

about

Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications Chromatin targeting drugs in cancer and immunity Molecular biology. EZH2 goes solo.Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics.Mutational analysis of Polycomb genes in solid tumours identifies PHC3 amplification as a possible cancer-driving genetic alteration Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Targeting of cancer stem cells by inhibitors of DNA and histone methylation.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.Notch Represses Transcription by PRC2 Recruitment to the Ternary Complex.

P2860

Q26801380-D1635573-1737-4E88-A69D-A383311F1E91 Q26999888-2A3C564D-B2DE-4C6B-9F9F-EE87CC9D7893 Q34034771-11D3FA57-4953-4005-9C34-D735A539EF01 Q34326174-E612FFBB-4AE4-4028-8CF9-280793855B1F Q36916348-D5E654E8-7025-4ED5-9034-592C74C678C6 Q36931136-BE6DC359-185C-405F-B661-DFEBAF365A2A Q37182184-F7B5720C-6CBE-48FE-8871-C08F11F7D925 Q38240579-2DBF80EC-269B-40D6-B13A-17E6109B2AB4 Q38500320-4C1F28BF-9312-43F7-8999-51354531E0D5 Q39381251-909CB5DF-C38D-4A3B-8859-58FE3634C375 Q49914122-C6860194-1826-44EA-9D65-DCE1482B191E Q50355542-BDC6C70C-3A80-4088-8D50-A58771A0E9ED

P2860

Epigenetic therapy leaps ahead with specific targeting of EZH2.

http://www.wikidata.org/entity/Q34034378

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Epigenetic therapy leaps ahead with specific targeting of EZH2.

@ast

Epigenetic therapy leaps ahead with specific targeting of EZH2.

@en

Epigenetic therapy leaps ahead with specific targeting of EZH2.

@nl

type

label

Epigenetic therapy leaps ahead with specific targeting of EZH2.

@ast

Epigenetic therapy leaps ahead with specific targeting of EZH2.

@en

Epigenetic therapy leaps ahead with specific targeting of EZH2.

@nl

prefLabel

Epigenetic therapy leaps ahead with specific targeting of EZH2.

@ast

Epigenetic therapy leaps ahead with specific targeting of EZH2.

@en

Epigenetic therapy leaps ahead with specific targeting of EZH2.

@nl

P1433

Q34034378-D5DF38B5-0F0B-478B-9C57-9913ECB5E035

P1476

Q34034378-1B2BE5E9-9455-4A18-8F54-ACE50B5B8BDC

P2093

Q34034378-20804DA7-07DA-4434-A9EC-C7B98BA51EC2

P2860

Q34034378-01A01104-A1D7-46F4-A26D-337D02379707

Q34034378-11DA2C90-562A-4BA5-8F96-87369ABBF1B5

Q34034378-1B49F19F-D952-48EA-A1E7-A6F3C18A8F41

Q34034378-225BC04A-FB24-49CE-A0A8-166E9D6EAAB3

Q34034378-2409B0F7-FD46-44DA-B3E0-E7A2278D7ACD

Q34034378-4D4C6F2C-EE52-4A1E-9D36-8B0AE61D2032

Q34034378-9BBDB812-9523-4815-9FD2-2A1F4F264D04

Q34034378-B5F8A227-76FF-4B6D-B46A-9ED372B68AA8

Q34034378-D47628C1-3663-4E93-A943-C728D6497E2E

Q34034378-FAF4D150-7A26-4B40-A00B-EDB55980AA15

P304

Q34034378-1E61D079-043F-4343-B48E-1B32BDEA2295

P31

Q34034378-2662B7D8-531A-4585-B545-98CFA1BA9F70

P356

Q34034378-57810DC5-AFEC-4285-85D9-7F8BABD4F57A

P433

Q34034378-C0DA0A80-6503-4BF7-994A-2B65C701D9B8

P478

Q34034378-F91BCEBD-3078-448B-8362-166768B40DD6

P577

Q34034378-866CF576-90C1-4C96-9AE6-BEC2FDFC2D3F

P5875

Q34034378-1873C215-B67E-4E1D-93FC-54F20E668392

P698

Q34034378-DE5117D0-3759-4DBC-8CFB-1FA35D605E47

P932

Q34034378-D0434944-99A2-4C85-BE4A-59957305BCE4

P356

J.CCR.2012.10.016

P1433

P1476

Epigenetic therapy leaps ahead with specific targeting of EZH2.

@en

P2093

Ari Melnick

http://www.w3.org/2001/XMLSchema#string

P2860

A decade of exploring the cancer epigenome - biological and translational implications

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Aberrations of EZH2 in cancer.

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.

DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.

EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.

Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement.

Polycomb group protein ezh2 controls actin polymerization and cell signaling.

P304

569-570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2012.10.016

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233422716

http://www.w3.org/2001/XMLSchema#string

P698

23153531

http://www.w3.org/2001/XMLSchema#string

P932

3732786

http://www.w3.org/2001/XMLSchema#string